BoNT/A Sequence Variant Composition for Improved Tissue Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for botulinum toxin pharmaceutical compositions with improved properties, particularly in reducing the diffusion of biologically active BoNT/A away from the administration site and enhancing tissue retention.
Innovation Solution
A 150 kDa BoNT/A variant with a C-terminal truncated light chain is developed, and fermentation conditions are optimized with increased CO2 levels and lower temperatures to reduce the amount of truncated BoNT/A, resulting in a 900 kDa BoNT/A complex with a controlled ratio of truncated to full-length variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard fermentation conditions are used, then productivity is maintained, but the amount of truncated BoNT/A increases causing reduced tissue retention
Solution Approach 1:
The patent applies parameter changes by modifying fermentation conditions (increasing CO2 concentration and adjusting temperature) to control the production of truncated BoNT/A variants. This resolves the contradiction by optimizing parameters to reduce harmful truncated forms while maintaining acceptable productivity levels.
Solution Approach 2:
The patent converts the harmful effect of truncated BoNT/A (which causes reduced tissue retention) into a controllable parameter. By establishing specific fermentation conditions, the truncated variants are minimized and converted from a harmful byproduct into an acceptable component within defined ratio limits, thereby improving overall product reliability.
2Ease of manufacture
If truncated BoNT/A variant is present, then production complexity is reduced, but electrostatic interactions become unfavorable reducing tissue retention
Solution Approach 1:
The patent changes the charge distribution parameters of the BoNT/A complex by controlling the ratio of truncated to full-length variants through fermentation optimization. This resolves the contradiction by maintaining production simplicity while ensuring the electrostatic properties favor tissue retention through controlled variant composition.
3Manufacturing precision
If ratio of truncated to full-length BoNT/A is not controlled, then manufacturing precision is reduced, but production cost is lowered
Solution Approach 1:
The patent establishes specific parameter ranges for fermentation conditions (CO2 concentration, temperature) that naturally control the variant ratio. This resolves the contradiction by achieving manufacturing precision through parameter optimization rather than complex post-production separation processes.
Solution Approach 2:
The patent applies preliminary action by controlling the variant ratio during the fermentation process itself, rather than attempting to separate variants after production. This preliminary control simplifies manufacturing while ensuring the desired precision in variant composition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized BoNT/A complex exhibits improved tissue retention by minimizing unfavorable electrostatic interactions, thereby reducing diffusion and enhancing the effectiveness of the toxin at the administration site.
Implementation Method 1
The more negatively charged truncated BoNT/A variant may display a shorter tissue retention time than the full-length BoNT/A species at the site of administration due to unfavorable electrostatic interactions between the truncated BoNT/A variants described herein and the anionic extracellular components (such as cell membranes and heparin sulphate proteoglycans) at the site of administration
Implementation Method 2
The present disclosure also describes that increasing the concentration of CO2 during the fermentation of Clostridium botulinum and using a temperature that is lower than the standard fermentation temperature during fermentation (either for a short period of time (i.e., cold shock) or continuously) both can reduce the amount of truncated 150 kDa BoNT/A
Data Source
AI summary
Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain.